12:00 AM
 | 
May 15, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Evista raloxifene selective estrogen receptor modulator regulatory update

The EU granted marketing approval for Evista to treat postmenopausal osteoporosis, in...

Read the full 39 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >